Editas Medicine, Inc. (EDIT) Stock Analysis
A live, multi-source view of Editas Medicine, Inc. (EDIT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 87 employees · editasmedicine.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Editas Medicine, Inc. (EDIT) had a market capitalization of $496.1M (forward -4.3) and a beta of 2.09; the shares traded in a 52-week range of $1.66 – $4.54 (10.4% over the year).
- Market cap
- $496.1M
- Enterprise value
- $299.9M
- Forward P/E
- -4.3
- Price / book
- 4.71
- EPS (trailing)
- $-0.69
- EPS (forward)
- $-0.75
- Payout ratio
- 0.0%
- 52-week range
- $1.66 – $4.54
- 52-week change
- 10.4%
- Beta
- 2.09
- Average volume
- 2.3M
- Shares outstanding
- 153.6M
- Short % of float
- 16.10%
- Profit margin
- -157.3%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Editas Medicine, Inc. (EDIT) last closed at $2.65 (the last completed close before that scan).
Technicals at the scan: RSI 40 (neutral territory), price -12.5% versus its 20-day average, 20-day versus 50-day average spread +1.0%, MACD histogram -0.05.
Sentiment inputs: 67% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; Reddit mentions +50% over 24 hours; analyst consensus score 56/100.
Next scheduled company event: in 59 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of EDIT; corporate insiders filed 0 buys and 5 sells (3 distinct filers, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Linda Burkly (0B/2S), Amy Parison (0B/2S), Gilmore Neil O'neill (0B/1S). Who is trading what
RapidTradeView pick record
EDIT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Editas Medicine, Inc. (EDIT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell EDIT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.